Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications.

In vitro screening of 307 drugs with various clinical indications (cardiotropic, neurotropic, antibacterial, etc.) has revealed 6 compounds which displayed remarkable antiretroviral activity. Three of these drugs had a tendency to have undesirable side effects and were thus excluded from further consideration. Remaining three, i.e., Xantinol Nicotinate, Tardiferon, and Trental may become valid candidates for inclusion into antiviral regimens such as HAART. In vitro tests have shown that xantinol and trental display synergistic effect with azidothymidine, inhibit the replication AZT-resistant strains of HIV, and have no competing undesirable activities. These compounds should be evaluated in safety studies to determine optimal doses for patients with HIV. If these studies confirm in vitro results these compounds may become valid candidates as safe and affordable means to be added into the arsenal of antiretroviral drugs.

Therapeutic AIDS vaccines.

Therapeutic HIV vaccines represent promising strategy as an adjunct or alternative to current antiretroviral treatment options for HIV. Unlike prophylactic AIDS vaccines designed to prevent HIV infection, therapeutic vaccines are given to already infected individuals to help fight the disease by modulating their immune response. The first immunotherapeutic trial in AIDS patients was conducted in 1983. Since then several dozen conventional therapeutic vaccine trials have been carried out. Unfortunately, the results have consistently shown that while HIV-specific immune responses were evident as a result of vaccination, the clinical improvement has been seldom observed. The instances of the apparent clinical benefit were invariably associated with unconventional vaccines that acted in accord with the principles of alloimmunization and/or autologous vaccination. All such vaccines were derived from the blood of HIV carriers or a cell culture and thus they inherently contained allo- or self-antigens unrelated to HIV. This intriguing observation raises the issue whether this clinically successful approach has been unduly neglected. The current strategy biased toward vaccines, which have shown little evidence of clinical efficacy, needs to be diversified and supplemented with research on alternative vaccine approaches geared toward immune tolerance induction.

Sorbicillactone A: a structurally unprecedented bioactive novel-type alkaloid from a sponge-derived fungus.

This chapter deals with the discovery of sorbicillactone A, as an illustrative example of the fruitful cooperation within BIOTECmarin--its isolation and chemical characterization, and its biological activities. Sorbicillactone A was isolated from a strain of Penicillium chrysogenum cultured from a sample of the Mediterranean sponge Ircinia fasciculata; it possesses a unique bicyclic lactone structure, seemingly derived from sorbicillin. Among the numerous known sorbicillin-derived structures, it is the first found to contain nitrogen and thus the first representative of a novel type of 'sorbicillin alkaloids', apparently originating from a likewise remarkable biosynthesis. Furthermore, the compound exhibits promising activities in several mammalian and viral test systems, in particular a highly selective cytostatic activity against murine leukemic lymphoblasts (L5178y) and the ability to protect human T cells against the cytopathic effects of HIV-1. These properties qualify sorbicillactone A or one of its derivatives for animal and (hopefully) also future therapeutic human trials.

Suppression of PrP(Sc)- and HIV-1 gp120 induced neuronal cell death by sulfated colominic acid.

The scrapie prion protein (PrP(Sc)) has been shown to induce apoptosis of rat cortical neurons in vitro. Here we demonstrate that the toxic effect displayed by PrP(Sc) can be blocked by sulfated colominic acid (polymer of N-acetylneuraminic acid). This compound acts neuroprotectively at a concentration of > or = 0.3 microg/ml when preincubated with the neurons or PrP(Sc). Rat cortical cells also undergo apoptosis after incubation with the HIV-1 coat protein gpl20 in vitro. This effect was abolished also by sulfated colominic acid when preincubated with the cells or gpl20. Addition of 0.3 microg/ml of compound resulted in an increase in cell viability by about 1.6-1.9-fold compared to cultures incubated for 18 h with 30 ng/ml of PrP(Sc) or 20 ng/ml of gpl20 alone (containing about 40% viable cells). Sulfated colominic acid does not act as antagonist of NMDA receptor channels at concentrations of up to 3 microg/ml when co-administered with 100 microg/ml of NMDA. It displayed a strong cytoprotective effect on human T lymphoblastoid CEM cells exposed to HIV-1; a 50% protection occurred after preincubation of the cells with 0.43 microg/ml of compound. At the same concentration, the compound caused an inhibition of HIV-1-induced syncytium formation. Sulfated colominic acid may be a promising compound for treatment of dementia caused by PrP(Sc) and HIV-1 infections.

[Serological properties of HIV-1 isolates from the focus of an epidemic in the Gomel region of the Belarus Republic (1996)]. / Serologicheskie svoistva izoliatov VICh-1 iz ochaga épidemii v Gomel'skoi oblasti Respubliki Belarus' (1996 g.).

Immunoreactivity of sera obtained in 1996 from HIV-1-infected intravenous narcomaniacs from an epidemic focus in Gomel region, Belarus, is studied with a panel of 10-16-component synthetic peptides simulating apical epitope of surface glycoprotein gp120 V3 loop of HIV-1 variants. Comparative analysis of resultant spectra with representative immunoreactivity spectra of sera from a sampling of HIV-1-positive sera collected in 1986-1997 in different regions of the former USSR demonstrated a high homogeneity of immunoreactivity spectra of sera from Gomel region. Serotypes of HIV-1 A/C variants circulating in populations of intravenous narcomaniacs in the focus in Gomel region in 1996 and in Southern and South-Eastern Ukraine in 1995-1996 are similar. This confirms a previous conclusion about the prevalence of A/C serotype among intravenous narcomaniacs in the former USSR.

[A complex approach to the diagnosis of HIV-1 infection: the use of the polymerase chain reaction as an alternative confirmatory test]. / Kompleksnyi podkhod k diagnostike VICh-1-infektsii: ispol'zovanie polimeraznoi tsepnoi reaktsii v kachestve al'ternativnogo podtverzhdaiushchego testa.

The results of the three-year observation of female patient St. in whose blood antibodies to HIV disappeared in the course of time and the results of the laboratory study of the blood sera of children born of HIV-infected mothers are presented. In these patients correct diagnosis could be made only with the use of a complex of virological and molecular-biological methods.

Interaction of 68-kDa TAR RNA-binding protein and other cellular proteins with prion protein-RNA stem-loop.

The RNA stem-loop structure of the trans-activating region TAR sequence of human immunodeficiency virus-1 mRNA is the binding site for a number of host cell proteins. A virtually identical set of proteins from HeLa nuclear extracts was found to bind to the predicted RNA hairpin element of prion protein (PrP) mRNA, as demonstrated in UV cross-linking/RNase protection and Northwestern assays. We show that the cellular TAR loop-binding protein, p68, is among those proteins which associate with PrP RNA. Competition experiments with various TAR RNA mutants revealed that binding of partially purified p68 to PrP RNA stem-loop occurs sequence-specifically. The 100-kDa 2-5A synthetase which is involved in the cellular antiviral defense was able to bind to PrP mRNA stem-loop in Northwestern blots with cytosolic proteins from HeLa cells treated with interferon. However, the PrP RNA failed to activate this enzyme in vitro, in contrast to TAR RNA.

Simultaneous introduction of distinct HIV-1 subtypes into different risk groups in Russia, Byelorussia and Lithuania.

OBJECTIVE: To investigate genotypes and serotypes of HIV-1 variants in Russia, Byelorussia and Lithuania. PATIENTS AND METHODS: Sera from 20 HIV-1-infected individuals were tested in an enzyme-linked immunosorbent assay (ELISA) with 19 V3 synthetic peptides, and serum HIV-1 V3 RNA was amplified and sequenced. RESULTS: Sequence comparison of the envelope V3 region among specimens tested revealed a 2-29% range nucleotide divergence, with a mean of 19%. Phylogenetic analysis from the homosexual men were shown to belong to subtype B, and all of the heterosexually infected individuals to subtype C. Sequences from the parenterally infected individuals were more heterogeneous. IOn the peptide ELISA three reactivity patterns were found. Serum samples from six out of seven homosexual men showed reactivity to peptides p108 or p110 representing V3 amino-acid sequences found in US/West European HIV-1 isolates. Serum samples from six of seven individuals who had acquired HIV-1 through heterosexual contacts were reactive to peptide p169. Four out of six parenterally infected patients had peak reactivity to p168. CONCLUSION: Distinct HIV-1 variants were found in Russia, Byelorussia and Lithuania, which were introduced simultaneously in the mid-1980s. This diversity was shown to be associated with the route of transmission. Homosexual men appeared to be infected with subtype B and heterosexually infected individuals with subtype C HIV-1 variants. HIV-1 subtypes A, C, D and G were found among parenterally infected individuals.

PIP: HIV-1 variants show a relatively high level of genomic and antigenic diversity. This heterogeneity is particularly high in the V3 domain of envelope glycoprotein gp120, which is implicated in a number of biological properties of HIV-1, including cell tropism, infectivity, and cytopathogenicity; it is also a target for both humoral and cellular immune response. At least nine subtypes of HIV-1 have been identified. Subtypes A-H are phylogenetically equidistant and shown to be geographically associated with different subcontinents. Subtype B is most prevalent in North and South America and western Europe. Subtypes A, C, D, G, and H are found frequently in sub-Saharan countries, while subtype C is also found in India. Subtype E sequences have been found in patients from Thailand and Central Africa, and subtype F has been described in Romania and Brazil. This study reports findings from an investigation of genotypes and serotypes of HIV-1 variants in Russia, Byelorussia, and Lithuania. Sera from 15 HIV-1-infected men and 5 HIV-1-infected females were tested by ELISA with 19 V3 synthetic peptides with amplified and sequenced serum HIV-1 V3 RNA. Sequence comparison of the envelope V3 region among specimens tested revealed a 2-29% range of nucleotide divergence, with a mean of 19%. Distinct variants of HIV-1 were found in Russia, Byelorussia, and Lithuania, which were introduced simultaneously in the mid-1980s. The diversity was shown to be associated with the route of transmission. Homosexual men appeared to be infected with subtype B compared to heterosexually infected individuals with subtype C HIV-1 variants. HIV-1 subtypes A, C, D, and G were found among parenterally-infected individuals. These findings are based upon the three peptide reactivity patterns identified by ELISA. Serum samples from six out of seven homosexual men showed reactivity to peptides p108 or p110 representing V3 amino-acid sequences found in US/West European HIV-1 isolates. Serum samples from six out of seven individuals who had acquired HIV-1 through heterosexual contacts were reactive to peptide p169, and four out of six parenterally infected patients had peak reactivity to p168.

[The use of the polymerase chain reaction in modelling HIV infection in animals]. / Ispol'zovanie polimeraznoi tsepnoi reaktsii pri modelirovanii VICh-infektsii na zhivotnykh.

The data on observations, lasting over the period of 6 months, on cotton rats given large doses of highly replicating strain HIV-1zmb by retrobulbar and intraperitoneal injections are presented. The study revealed that in all animals subjected to intraperitoneal infection lymphoid tissue contained integrated areas of protovirus DNA of HIV-1 three months later and cerebral tissue, five months later. Six months after retrobulbar infection the specimens of lymphoid tissue contained protovirus DNA in 100% of cases and the specimens of cerebral tissue, in 80% of cases. Clinical and morphological investigations established the presence of the inflammatory process, though no signs of HIV replication in the body of animals were detected. Polymerase chain reaction is proposed as criterion for the evaluation of HIV infection in animals.

[Morphological characteristics of the course of HIV infection in laboratory animals]. / Morfologicheskaia kharakteristika techeniia VICh-infektsii u laboratornykh zhivotnykh.

The integrative form of infection was obtained in cotton rats intraperitoneally or retrobulbarly infected with the highly-productive strain Zmb HIV-1. Clinically, it appeared as reduced animal weight gain and high mortality rates in the disease terminal stage. The proviral DNA was detected by the polymerase chain reaction in the genomes of cerebral and splenic cells in most animals. A comprehensive study of the time course of morphological changes within 6 months showed impairments in some CNS cells, giving rise to glial nodules and neurone dystrophy. It should be noted that the most profound changes were observed when the virus had been intraperitoneally injected. It was found that some pathomorphological changes were similar to those seen in human neuro-AIDS. In the spleen, HIV-1 first stimulated an immune response, caused an increase in the extent of white bulb follicles and an active formation of germinative centers, then involution of lymphoid formations took place.

Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures.

Rat cortical cells were incubated with the Scrapie prion protein, PrionSc. At concentrations of 3 ng/ml of PrionSc and higher, the viability of the cells decreased significantly after a 12-h incubation period. Simultaneously, the degree of DNA fragmentation increased. In control experiments with antibodies against PrionSc, PrionSc lost its deleterious effect on neurons. PrionSc did not affect the viability of astrocytes. Drugs known to block NMDA receptor channels, such as memantine (1-amino-3,5-dimethyl-adamantane) (Mem), its analogue 1-N-methylamino-3,5-dimethyl-adamantane as well as (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) prevented the effect of PrionSc. Production of PrionSc in the Scrapie prion-infected subclone of N2 a cells (ScN2 a cells) was not affected by memantine. We conclude that antagonists of the NMDA receptor-channel complex (i) abolish the PrionSc-induced neuronal injury in vitro, and (ii) display no influence on the synthesis and/or the processing of PrionSc.

Mode of action of the anti-AIDS compound poly(I).poly(C12U) (Ampligen): activator of 2',5'-oligoadenylate synthetase and double-stranded RNA-dependent kinase.

The mismatched double-stranded RNA (dsRNA), poly(I).poly(C12U), also termed Ampligen, exhibits a strong antiviral and cytoprotective effect on cells (human T-lymphoblastoid CEM cells and human T-cell line H9) infected with the human immunodeficiency virus type 1 (HIV-1). Untreated H9 cells infected with HIV-1 start to release the virus 3 days post-infection, while in the presence of 40 micrograms/ml (80 micrograms/ml) of poly(I).poly(C12U) the onset of virus production and release is retarded and does not occur before day 5 (day 6). We demonstrate that poly(I).poly(C12U) markedly extends the duration of the transient increase of 2',5'-oligoadenylate (2-5A) synthetase mRNA level and activity preceding virus production after infection of cells with HIV-1. Treatment of HeLa cells with poly(I).poly(C12U) was found to cause a significant increase in total (activated plus latent) 2-5A synthetase activity; no evidence was obtained that the level of latent (nonactivated) 2-5A synthetase is changed in cells treated with dsRNA plus interferon (IFN). Poly(I).poly(C12U) is able to bind and to activate 2-5A synthetase(s) from HeLa cell extracts. Addition of poly(I).poly(C12U) to HeLa cell extracts results in production of longer 2-5A oligomers (> or = 3 adenylate residues), which are better activators of RNase L. Both free and immobilized poly(I).poly(C12U) also bind to the dsRNA-dependent protein kinase (p68 kinase), resulting in autophosphorylation of the enzyme. Activation of the kinase by the free RNA occurs within a limited concentration range (10(-7) to 10(-6) grams/ml). Addition of HIV-1 Tat protein does not affect binding and activation of p68 kinase to poly(I).poly(C12U)-cellulose but strongly reduces the binding of the kinase to immobilized TAR RNA of HIV-1. We conclude that poly(I).poly(C12U) may antagonize Tat-mediated down-regulation of dsRNA-dependent enzymes.

[The use of a primary astrocyte culture for modelling HIV neurological infection]. / Ispol'zovanie pervichnoi kul'tury astrotsitov dlia modelirovaniia VICh-neiroinfektsii.

The article deals with the results of the experiment substantiating the in vitro model of HIV neuro-infection. In this work primary glial (astrocytic) tissue cultures obtained from normal human and animal (guinea pig) brain tissue were used. As revealed in this investigation, the following phenomena could be observed in human brain tissue monolayer culture, infected with HIV and subsequently subcultured: (a) the stimulation of tissue-cell growth; (b) the formation of multinuclear glial cells; (c) the presence of virus-specific proteins in astrocyte cytoplasm, detected by immunofluorescent and electrophoretic techniques; (d) the presence of HIV-1 DNA provirus in infected astrocytes. Cyto-destruction was not observed, reverse transcriptase activity was absent.

Accumulation of transcripts coding for prion protein in human astrocytes during infection with human immunodeficiency virus.

The abnormal isoforms of the normal cellular prion protein (PrP), also termed Scrapie-associated fibril protein, are assumed to be one causative factor of spongiform encephalopathies. The mRNA of PrP contains stem-loop structures which are very similar to the human immunodeficiency virus-1 (HIV-1) cis-acting sequence TAR within the LTR; both structures contain the pentanucleotide CUGGG in the loop, and the uridine- and adenine-bulge in the stem. In this study, using purified HIV-encoded trans-activator, Tat, and HIV-1 TAR-RNA or PrP-mRNA containing the stem-loop structure, we demonstrate by use of gel-retardation and filter binding assays that Tat binds to TAR- and PrP-RNA with the dissociation constants of 2.9 or 37.0 nM, respectively, at a molar ratio of 0.7 mol of Tat to 1 mol of RNA fragment. The Tat-RNA (TAR or PrP) complexes bind to protein(s) in the nuclear matrix, isolated from human astrocytes (glial fibrillary acidic protein positive brain cells). Infection of astrocytes with HIV-1 resulted in an increased level of PrP mRNA. The data presented led us to assume that certain sequences in the PrP mRNA might be targets for proteins acting in trans.

[Status of collective immunity to hepatitis A virus in urban residents in Byelorussia]. / Sostoianie kollektivnogo immuniteta k virusnomu gepatitu A u gorodskogonaseleniia Belorussii.

The large immune stratum and intense collective immunity to virus hepatitis A among the urban population of Byelorussia are characteristic of hyperendemic territory. The geometric mean of the antibody titer has been noted to increase with age, which is probably due to repeated infections of persons who have already had the disease. The use of this value for the characterization of collective immunity and epidemiological situation has been proposed.

[The clinico-pathogenetic characteristics of Kaposi's sarcoma]. / Kliniko-patogeneticheskie osobennosti sarkomy Kaposhi.

The paper is concerned with clinicomorphological characteristics of endemic, immune and epidemic (AIDS-associated) forms of Kaposi's sarcoma (KS). Recent experimental and clinical evidence suggests pathogenic contribution to KS of virus-induced depression of sex-linked genes and immunosuppression. Combined action of these factors should be regarded when specifying current presentation of KS.

[The strain features of the HIV-1 circulating in the USSR based on data from a study of its properties in cell cultures]. / O shtammovykh osobennostiakh tsirkuliruiushchego v SSSR VICh-1 po dannym izucheniia ego svoistv v kletochnykh kul'turakh.

Both variants of HIV-1 reported in the literature: slow/low and rapid/high types, were detected among the strains isolated from the subjects examined in 4 foci of HIV-1 infection in the south of the RSFSR and Byelorussia. All the 17 strains isolated in the southern RSFSR foci belonged to the slow/low type and had a low and unstable replication potential in donor peripheral blood mononuclear cells and in MT-4 cell line. All of them were isolated from subjects with asymptomatic infection and from children with initial clinical manifestations of the disease. Only one strain isolated in Byelorussia belonged to the rapid/high type. Its replicative activity was very similar to that of the classical HIV-1--HTLV-IIIB strain. Long-term (up to 7 months) propagation of slow/low strains did not result in any increase of their replicative activity. The capacity to form syncytia was found not only in the rapid/high type strains but also in the majority of slow/low strains under study.